Cancer patients get continued access to key therapy in extension study

NCT ID NCT05112965

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment available while monitoring for serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASMS

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, 100142, China
Cancer Hospital of Shandong First Medical University

Jinan, Shandong, 250117, China
Changchun Cancer Hospital

Changchun, 130000, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital

Zhengzhou, 450008, China
Hunan Cancer Hospital

Changsha, 410013, China
Jiangsu Cancer Hospital

Nanjing, 211100, China
Jilin Cancer Hospital

Changchun, 132013, China
Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, 510515, China
Peking Union Medical College Hospital

Beijing, 100730, China
Shanghai Chest Hospital

Shanghai, 200000, China
Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, 310016, China
The 2nd Hospital of Tianjin Medical University

Tianjin, 300211, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, 510120, China
Tianjin Cancer Hospital

Tianjin, 300060, China
Union Hospital of Tongji Medical College, Dept. of Cancer Center

Wuhan, Hubei, 430022, China
Zhejiang Cancer Hospital

Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.